Q4 2024 ADDvise Group AB (publ) Earnings Call Transcript
Key Points
- ADDvise Group AB (FRA:Q3I) reported a solid Q4 2024 with net sales of SEK 442 million, marking an 11% year-on-year growth.
- The company achieved an EBITDA of SEK 89 million, resulting in a 20% EBITDA margin for the quarter.
- Organic growth for the year 2024, excluding pharma and clinical trials, was 7%.
- The company has a strong liquidity position with approximately SEK 356 million in cash and short-term investments.
- ADDvise Group AB (FRA:Q3I) is focusing on profitable growth and aims to double its EBITDA every five years.
- The company experienced a negative organic growth of minus 3% in Q4 2024, although this was an improvement from the previous quarter's minus 25%.
- EBITDA decreased by SEK 26 million compared to the previous year, primarily due to normalized earnouts revaluation.
- The healthcare segment reported an organic sales drop of 1% and a lower EBITDA margin of 14% for the quarter.
- Net leverage at the end of 2024 was 3.8 times EBITDA, above the long-term target of three times.
- The company is facing challenges in the pharma and clinical trials segments, which have impacted profitability compared to 2023.
Welcome to Advise Group Q4 2024 report presentation. (Operator Instructions)
Now I will hand the conference over to Chief Executive Officer Staffan Torstensson and acting Chief Financial Officer Johan Irwe. Please go ahead.
()- -
Thank you and once again, welcome to Advice Group Q4 2024 earnings call. As usual, we will, Take you through business update and then financial performance and a Q&A session. Q4 was a solid quarter. Our net sales came in at SEK 442 million, which takes us to a year-on-year growth of 11%.
However, we continue to see challenging pharma and clinical trials comparables. Following 2023's stellar performance, but we saw a clear trend shift in the quarter. That took us to a negative organic growth isolated in the quarter of minus 3% compared to last quarter where we came in at minus 25%.
EBITDA came in at SEK 89 million, which takes us to a 20% EBITDA margin. To give you some colour on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
